BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9792976)

  • 21. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.
    Spencer JA; Chng WJ; Hudson E; Boon AP; Whelan P
    Br J Radiol; 1998 Nov; 71(851):1130-5. PubMed ID: 10434906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma.
    Díaz-Martín MA; Traba ML; De La Piedra C; Guerrero R; Méndez-Dávila C; De La Peña EG
    Scand J Clin Lab Invest; 1999 Apr; 59(2):125-32. PubMed ID: 10353326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen.
    Kataoka A; Yuasa T; Kageyama S; Tsuchiya N; Habuchi T; Iwaki H; Narita M; Okada Y; Yoshiki T
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):480-4. PubMed ID: 16909972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer.
    Wolff JM; Bares R; Jung PK; Buell U; Jakse G
    Urol Int; 1996; 56(3):169-73. PubMed ID: 8860738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival markers related to bone metastases in prostate cancer.
    Salminen EK; Kallioinen MJ; Ala-Houhala MA; Vihinen PP; Tiitinen SL; Varpula M; Vahlberg TJ
    Anticancer Res; 2006; 26(6C):4879-84. PubMed ID: 17214355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The value of pretreatment clinical and biochemical parameters in patients with newly diagnosed untreated prostate carcinoma and no indications for bone metastases on the bone scintigram.
    Stokkel M; Zwinderman A; Zwartendijk J; Pauwels E; van Eck-Smit B
    Eur J Nucl Med; 1997 Oct; 24(10):1215-20. PubMed ID: 9323261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors in metastatic prostate cancer.
    Yigitbasi O; Ozturk U; Goktug HN; Gucuk A; Bakirtas H
    Urol Oncol; 2011; 29(2):162-5. PubMed ID: 19450995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer.
    Miller PD; Eardley I; Kirby RS
    Br J Urol; 1992 Sep; 70(3):295-8. PubMed ID: 1384920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Measurement of skeletal alkaline phosphatase in prostatic carcinoma. Preliminary report].
    Casetta G; Gamba P; Piana P; Pecchio F; Tizzani A
    Minerva Urol Nefrol; 1995 Mar; 47(1):9-12. PubMed ID: 7570264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levels of prostate specific antigen that predict skeletal spread in prostate cancer.
    Pantelides ML; Bowman SP; George NJ
    Br J Urol; 1992 Sep; 70(3):299-303. PubMed ID: 1384921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer.
    Ataus S; Citçi A; Alici B; Onder AU; Sönmezoğlu K; Erözenci A; Solok V
    Int Urol Nephrol; 1999; 31(4):481-9. PubMed ID: 10668943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer.
    Kikuchi E; Nakashima J; Ishibashi M; Ohigashi T; Oya M; Nakagawa K; Miyajima A; Murai M
    Urology; 2006 Aug; 68(2):371-5. PubMed ID: 16904455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.
    Jung K; Stephan C; Semjonow A; Lein M; Schnorr D; Loening SA
    J Urol; 2003 Dec; 170(6 Pt 1):2302-5. PubMed ID: 14634401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
    Amico S; Liehn JC; Desoize B; Larbre H; Deltour G; Valeyre J
    Clin Nucl Med; 1991 Sep; 16(9):643-8. PubMed ID: 1718651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate.
    Bruwer G; Heyns CF; Allen FJ
    Eur Urol; 1999; 35(3):223-7. PubMed ID: 10072624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis.
    Wymenga LF; Groenier K; Schuurman J; Boomsma JH; Elferink RO; Mensink HJ
    BJU Int; 2001 Aug; 88(3):231-5. PubMed ID: 11488735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
    Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
    Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M; Noda S
    J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone scanning--who needs it among patients with newly diagnosed prostate cancer?
    Hirobe M; Takahashi A; Hisasue S; Kitamura H; Kunishima Y; Masumori N; Iwasawa A; Fujimori K; Hasegawa T; Tsukamoto T
    Jpn J Clin Oncol; 2007 Oct; 37(10):788-92. PubMed ID: 17911377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.